US › Healthcare

aTyr Pharma, Inc. (ATYR)

US · Healthcare · Biotechnology

$0.53+7.56%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.8M
Profit YoY
+27.5%
EPS
$-0.11
EPS estimate
$-0.14

EPS came in at -0.11 against a street estimate of -0.14 — a beat of 22.8%.

Key statistics

Market cap
$48.2M
Forward P/E
0.0
P/B
0.83
Book value
$0.59
EPS (TTM)
$-0.74
52-week high
$6.50
52-week low
$0.40
50-day MA
$0.51
200-day MA
$0.74
Beta
0.52

Analyst view

Analysts rate aTyr Pharma, Inc. a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $2.86.

Shareholding

Insiders
2.45%
Institutions
46.35%

Largest institutional holders

FundStake
FMR Inc15.00%
Federated Hermes Inc10.72%
BlackRock Inc6.57%
Vanguard Group Inc5.06%
UBS Group AG3.94%
Vanguard Capital Management, LLC3.89%
Geode Capital Management, LLC2.43%
State Street Corp1.79%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for aTyr Pharma, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.